Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
CautiousOptimist
Thanks for your research. I sure we will follow the same trend.
And my thoughts also, although not six figures enough to cause a stressful week.
I am reassured by Alistairs Q&A session and that he is focused of delivering a quality covid produce to market, which is why we have the current t turbulence. Once news comes out regarding the LFD hopefully we will have a less stressful journey.
Good luck all.
Sir Alistair delivered great performance. Many more questions and very well answered.
The key thing that came across is Avacta will deliver a quality LFD but will not be rushed, they have to get it right and how transformation it can be for the company.
I'll sleep well tonight, we are in safe hands.
I thought the presentation was a useful refresher with a little more detail regarding, lining up manufacturing of the LFD once they are ready. Sir Alistair is consistent with his messages and is not wanting to raise expectations too much. I am sure we will get a high quality LFD before the end of the month. I would not be surprised to see and RNS before the Cytiva Webinar on the 17th, but if not I will hold and wait. It is frustrating to see the shinanigans with regards to share price, but I am convinced Avacta will deliver, for long term holders.
Good luck all.
As a new poster I just wanted to thank those very informed and knowledgeable posters who have helped me to get a far greater understanding of the possibilities here. I have only been invested in Greatland only a few months, but it's a pleasure to come onto this site and read the posts as there is alot of support and information. The majority of my other investments many of the chats deteriate to childish and personal attacks between posters.
Reading some of the posters earlier I was also one of those invested in sxx, which still leaves a nasty taste. But fingers crossed this will repair some of that damage.
We are all coming out this evening.
A few months ago I was told about an exciting company called Avacta who had potentially discovered a very exciting cancer treatment. I went off and researched and read about the Affimer technology and the potential with Covid testing and Cancer treatments. I quickly became excited not only with the potential, but mostly with the quality and professionalism of the CEO and the company. I first invested at 56p, then 84p, 93, 101 and a number of further top ups. I now average £1.11.
Like many others have posted the rapid drop and issue of additional shares led me to initally question the integrity of the CEO, but that only lasted a couple of hours, before I realised opportunity and benefit of the accelerated development of Avacta. Which will result in benefits for shareholders.
The last couple of weeks have been a rolecoaster seeing RNS arrive which I believed to be very positive to then see the share price drop. I believe those invested have been spoilt by the amount of regular RNS and now seem to expect one every 2 or 3 days. Which is leading to alot ramping and deramping and many hours of reading through all the postings.
Like many others I am extremely greatful to the quality and knowledgeable posters who have assisted in directing my research and understanding. I have also learnt to filter and walk away for the board when the games start.
I think I have found a gem in Avacta and am looking to hold and to try and enjoy the ride.
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Update on COVID-19 Antigen Diagnostic Test Development with Adeptrix
Highly specific prototype test detects the virus spike protein at clinically relevant concentrations
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that a BAMSTM diagnostic test for the COVID-19 infection, being developed with its partner Adeptrix (Beverly MA, USA), has reached prototype stage and can detect the coronavirus spike protein in model samples in the concentration range appropriate for a clinical diagnostic test.
The bead-assisted mass spectrometry ("BAMS") assay uses the Affimer reagents specific to the SARS-COV-2 virus recently developed by Avacta to capture the virus spike protein from the sample for rapid detection by mass spectrometry.
A prototype assay has now been developed and evaluated by Adeptrix using model samples containing the coronavirus spike protein. The unique method breaks up the spike protein captured from the samples by Affimer coated beads and is able to identify fragments of the spike protein using mass spectrometry, at concentrations in the range found in patient samples generated from standard throat swabs.
The combination of the selectivity of the Affimer reagents used to capture the virus spike protein with the precision and accuracy of mass spectrometry detection provides for a very high degree of specificity in the assay.
The next step in the development of the final product to run on the installed base of mass spectrometers in clinical laboratories around the world is to evaluate and optimise the BAMS assay using patient samples at laboratory sites in the UK and US which will be done imminently before moving to manufacturing, clinical validation to quantify the sensitivity and specificity and CE/FDA approval for professional use in the summer.
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
"I am very pleased with the rapid progress made by our partners at Adeptrix and delighted that the Affimer reagents that we have developed to detect the SARS-COV-2 spike protein are working very well in the BAMS assay. This bodes well for all our COVID-19 antigen test development programmes.
We are now looking forward to testing the prototype BAMS assay with patient samples in the UK very soon, whilst Adeptrix does the same at a site in the US. This will keep us on track for launch of a product for professional use in the summer.
A COVID-19 BAMS assay could provide highly sensitive and specific testing for up to a thousand samples per day in the hospital setting using standard equipment that is available but not currently used for coronavirus testing thus contributing significantly to an increase in global testing capacity.
We continue to make very good progress with Cytiva on the saliva-based antigen test and I look